Navigation Links
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Date:4/3/2011

l Research Institute (DCRI) at Duke University Medical Center and Chair of the Steering Committee for the study.  "For the first time, we've shown that active control of anticoagulation is possible; the hypothesis that this may lead to better ischemic and bleeding outcomes will no doubt be a focus of the REG1 Phase 3 development program."

"Developing a technology that can selectively control anticoagulation has been considered the 'holy grail' for cardiac intervention," said Roxana Mehran, MD, Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at the Mount Sinai School of Medicine.  "For years, it's been the goal of cardiologists and surgeons to discover a more targeted method of controlling anticoagulation for patients undergoing ACS procedures, and the Phase 2b RADAR results exhibit significant promise toward this objective."

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to person
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
2. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
3. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
4. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
8. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
9. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
11. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, ... Dr. Helen Torley , President and Chief Executive ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
(Date:11/26/2014)... 26, 2014 Senior Planning Services, providing ... a nonprofit organization providing the adult demographic education ... help seniors navigate the rough seas of applying for ... seniors on the topic of Medicaid eligibility and proper ... process of applying for this coverage. , Senior ...
(Date:11/26/2014)... November 26, 2014 ISI Telemanagement ... solutions, has been award the 2014 Lync ... This award comes as a great honor to ... the Lync ecosystem. Specifically, ISI offers an integrated ... of Lync communication, including voice, video, Lync IM, ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Call 866-997-4948 ... requirements or email the details on sales(at)researchmoz(dot)us , ... and drug discovery market 2014" with deep study of ... the result of high blood sugar. The global glucose ... linked to the growing number of diabetics in the ...
(Date:11/26/2014)... November 26, 2014 Bunion Bootie, the ... prices in an early celebration of the early holiday ... being offered at the promotional price of $29.95 each ... in addition to any automatic discounts applied when buying ... Bootie website for complete details. It’s simple: purchasing ...
(Date:11/26/2014)... Louisiana (PRWEB) November 26, 2014 ... pain relief and specialists in minimally invasive spine ... Samer Shamieh into the rapidly growing provider network ... The addition coincides with the network’s continuing ... medical treatment for Louisiana residents who are suffering ...
Breaking Medicine News(10 mins):Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... NORTH HOLLYWOOD, Calif., June 17 IPC The,Hospitalist Company, ... group practice, today announced that it continues to experience,favorable ... net,revenues to be in the range of $57 million ... range of $4.2 million to $4.6 million. Absent the,impact ...
... CEO Scott Kornhauser,announced the appointment of Bryan Hebert ... Hebert was a former consulting partner with,over 18 ... in the healthcare,industry., Mr. Hebert,s responsibilities will ... market share for Healthation. Prior to,joining Healthation, Mr. ...
... Men whose tumors recur after prostate cancer surgery are ... term if they undergo radiotherapy within two years of ... whose new tumors were growing fastest, according to results ... Hopkins Medical Institutions researchers reported June 18 in the ...
... in DNA, study finds, , , TUESDAY, June 17 (HealthDay ... when it comes to cancer risk, according to a ... research suggests that stringent dietary changes, getting more exercise ... hundreds of genes. Some of the changes positively ...
... HILL, N.C., June 17 Across industry sectors,sales ... common operational, strategic and time management practices,according to ... LLC., The study shows the client still ... spend 21 percent of their time,building solutions for ...
... the death rate and might need to be used ... News) -- Countering common medical theory, a new study ... many men whose prostate cancer recurs aggressively after surgery. ... that recurs after surgery seem to benefit from salvage ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 2Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 3Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 4Health News:Radiation therapy prolongs life in men with recurrent prostate cancer 2Health News:Lifestyle Changes Affect Cancer Genes 2Health News:Lifestyle Changes Affect Cancer Genes 3Health News:High-Performing Sales Forces Share Key Practices to Achieve Optimal Performance 2Health News:Radiation May Help When Prostate Cancer Returns 2Health News:Radiation May Help When Prostate Cancer Returns 3
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses....
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Medicine Products: